Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Balofloxacin is a novel, broad-spectrum fluoroquinolone antibiotic developed primarily for the treatment of bacterial infections. Its chemical identity is defined by the molecular formula C20H19F3N4O3 and the CAS registry number 186576-74-5. Structurally, it features a distinctive trifluoromethyl group at the 6-position and a piperazinyl ring substituted with a pyridine moiety, which contributes to its potent antimicrobial activity and favorable pharmacokinetic profile.
This agent functions by inhibiting bacterial DNA gyrase and topoisomerase IV, essential enzymes required for DNA replication, transcription, repair, and recombination. By disrupting these processes, Balofloxacin effectively halts bacterial cell division, leading to cell death. It exhibits strong bactericidal activity against a wide range of Gram-positive and Gram-negative pathogens, including methicillin-resistant *Staphylococcus aureus* (MRSA), penicillin-resistant *Streptococcus pneumoniae*, *Escherichia coli*, and *Pseudomonas aeruginosa*. Notably, it maintains efficacy against many strains that have developed resistance to earlier-generation quinolones.
The primary clinical application of Balofloxacin involves treating respiratory tract infections, such as community-acquired pneumonia and acute exacerbations of chronic bronchitis. Additionally, it shows promise in managing complicated urinary tract infections and skin and soft tissue infections due to its excellent tissue penetration and high oral bioavailability. The drug is characterized by a long half-life, allowing for once-daily dosing regimens, which improves patient compliance. Furthermore, its unique structure minimizes cross-resistance with other fluoroquinolones, making it a valuable therapeutic option in scenarios where standard treatments fail. While generally well-tolerated, potential side effects may include gastrointestinal disturbances, dizziness, and rare instances of tendonitis or QT prolongation, necessitating careful monitoring during therapy. As an important addition to the fluoroquinolone class, Balofloxacin represents a significant advancement in combating multidrug-resistant bacterial infections globally.